LAPATINIB Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lapatinib, and when can generic versions of Lapatinib launch?
Lapatinib is a drug marketed by Natco Pharma Ltd and Teva Pharms Usa Inc and is included in two NDAs.
The generic ingredient in LAPATINIB is lapatinib ditosylate. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the lapatinib ditosylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lapatinib
A generic version of LAPATINIB was approved as lapatinib ditosylate by NATCO PHARMA LTD on September 29th, 2020.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LAPATINIB?
- What are the global sales for LAPATINIB?
- What is Average Wholesale Price for LAPATINIB?
Summary for LAPATINIB
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| DailyMed Link: | LAPATINIB at DailyMed |
US Patents and Regulatory Information for LAPATINIB
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Natco Pharma Ltd | LAPATINIB DITOSYLATE | lapatinib ditosylate | TABLET;ORAL | 203007-001 | Sep 29, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Teva Pharms Usa Inc | LAPATINIB DITOSYLATE | lapatinib ditosylate | TABLET;ORAL | 217968-001 | Aug 16, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
